Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.45 |
| ▸ | ACACB | O00763 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333769 | 0.92 | ACACB (0.44) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL6333404 | 0.92 | MMP1 (0.46) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL6331208 | 0.91 | KMT2A (0.49) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL6331205 | 0.91 | KMT2A (0.49) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL6331352 | 0.91 | KMT2A (0.50) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL7028880 | 0.86 | SMN1; SMN2 (0.39) | MMP1MMP9MMP13ADAM17KMT2A | |
| SCHEMBL7028093 | 0.84 | LMNA (0.37) | MMP1MMP9MMP13ADAM17KMT2A | |
| SCHEMBL6332577 | 0.83 | ACACB (0.45) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL6331353 | 0.82 | KMT2A (0.48) | MMP1MMP9MMP13ADAM17ACACB | |
| SCHEMBL6340627 | 0.82 | KMT2A (0.44) | MMP1MMP9MMP13ADAM17ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864392-B2 | α-Sulfin and α-Sulfonamino amide derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040092401-A1 | Novel alpha-sulfin and alpha-sulfonamino amide derivatives | SYNGENTA CROP PROTECTION, INC. | 2004-05-13 | — | — | US | disclosed |
| EP-1272460-A1 | NOVEL ALPHA-SULFIN- AND ALPHA-SULFONAMINO ACID AMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001079161-A1 | NOVEL α-SULFIN- AND α-SULFONAMINO ACID AMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092401-A1 | Novel alpha-sulfin and alpha-sulfonamino amide derivatives | SULT1A1, STS, SULT2A1 | MMP1 4073/4885MMP9 4268/4885MMP13 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.